Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen, Celgene, Vertex Pharmaceuticals, MannKind, and Peregrine Pharmaceuticals Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, June 18, 2013 NEW YORK, June 18, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Amgen Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Amgen Inc. Research Report On June 13, 2013, Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has sanctioned a new indication for XGEVA (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone (GCTB) that is unresectable or where surgical resection is likely to result in severe morbidity. XGEVA was accredited following a priority review by the FDA. "With today's XGEVA FDA approval, Amgen can offer a much needed treatment option to patients who suffer from giant cell tumor of bone that cannot be adequately treated with surgery. Advances in our understanding of the underlying biology of this rare disorder have allowed Amgen to generate compelling clinical evidence to address the medical needs of patients and their healthcare providers," shared Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen. The Full Research Report on Amgen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/e763_AMGN] -- Celgene Corporation Research Report On June 13, 2013, Celgene Corporation (Celgene) announced findings from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain. The PALACE 3 study (evaluating 495 patients) demonstrated statistical significance in achieving the primary endpoint of American College of Rheumatology (ACR) 20 score at week 16 for patients receiving apremilast compared to placebo (PBO), (PBO, 19%; apremilast 20 mg BID, 29%; apremilast 30 mg BID, 43%; p<0.05 and p≤0.0001, respectively). Patients in the 30 mg BID active treatment arm also showed significant and sustained advancements in psoriasis-related endpoints, including Psoriasis Area Severity Index (PASI) 50 and PASI-75 at week 24. Comparable improvements in 30 mg BID-treated patients were also perceived in key secondary endpoints, including various measures of physical function, signs and symptoms, and quality of life. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/7541_CELG] -- Vertex Pharmaceuticals Incorporated Research Report On June 5, 2013, Vertex Pharmaceuticals Incorporated (Vertex Pharmaceuticals) announced that six abstracts from its cystic fibrosis (CF) program will be presented at the 36th European Cystic Fibrosis Society (ECFS) Conference in Lisbon, Portugal, June 12-15, 2013. Presentations will include data from Cohorts 2 and 3 of a Phase 2 study of lumacaftor (VX-809) combined with ivacaftor in people with the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, F508del, as well as data from a Phase 2 study of VX-661 combined with ivacaftor in people with two copies of the F508del mutation. Poster presentations will feature data on the use of KALYDECO (ivacaftor) in people with CF of ages 6 and older who have the G551D mutation will follow. The accepted abstracts have been published by the Journal of Cystic Fibrosis on the same date, and can be accessed at the "Session Planner" on the ECFS Conference website. Following these presentations, the slides will be available on the ECFS Conference website. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/ec92_VRTX] -- MannKind Corp. Research Report On June 11, 2013, MannKind Corp. (MannKind) announced that it will participate at the Wells Fargo Securities Research & Economics 2013 Healthcare Conference on Tuesday, June 18, 2013 at 2:55 p.m. (ET) at the InterContinental Hotel in Boston. Interested parties can access through a link to the live webcast of the presentations provided in the News & Events section of the Company's website. The Full Research Report on MannKind Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0b44_MNKD] -- Peregrine Pharmaceuticals Inc. Research Report On June 3, 2013, Peregrine Pharmaceuticals Inc. (Peregrine Pharmaceuticals) reported final data from its randomized, double-blind, placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer (NSCLC). An improvement in median overall survival (OS) of 11.7 months in the 3 mg/kg bavituximab plus docetaxel arm compared to 7.3 months in the combined control arm, with a persistent separation in the Kaplan Meier survival curves (HR=0.662) were seen in the final results from the Phase II trial. "Immunotherapies have shown significant promise in treating solid tumors and it is encouraging to see these latest results from bavituximab in second-line NSCLC. Bavituximab is a unique targeted immunotherapy with a novel mechanism of action that potentially synergizes well with other compounds currently being developed for oncology. I look forward to being involved in the upcoming Phase III trial and to seeing the potential of bavituximab in other indications and combinations," said Martin J. Edelman, M.D., Professor of Medicine at the University of Maryland Greenebaum Cancer Center. The Full Research Report on Peregrine Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/df4a_PPHM] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen,
Press spacebar to pause and continue. Press esc to stop.